Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AbbVie (NY: ABBV )

199.50 -1.01 (-0.50%)
Official Closing Price Updated: 7:00 PM EST, Nov 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,597,251
Open 201.15
Bid (Size) 199.66 (1)
Ask (Size) 200.00 (1)
Prev. Close 200.51
Today's Range 199.48 - 201.89
52wk Range 136.30 - 207.32
Shares Outstanding N/A
Dividend Yield 2.97%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
My Favorite Dividend King to Buy in November
This Dividend King truly wears the crown. 
Via The Motley Fool
Bristol-Myers Squibb Leads Biopharma Recovery With Almost 25% Growth In Market Cap, But Novo Nordisk And Lilly Suffer Market Setbacks
The global biopharmaceutical market saw a 2% increase in market capitalization in Q3 2024, led by growth from Bristol-Myers Squibb, Gilead Sciences, and Sanofi, despite challenges for Novo Nordisk and... 
Via Benzinga

Performance

YTD
+24.83%
+24.83%
1 Month
+2.65%
+2.65%
3 Month
+4.90%
+4.90%
6 Month
+23.70%
+23.70%
1 Year
+43.95%
+43.95%

More News

Read More
2 Dividend Kings That Would Have Doubled Your Money in 5 Years
Via The Motley Fool
Dividend Watch: Three Companies Boosting Quarterly Payouts
Via Talk Markets
What the Options Market Tells Us About AbbVie
Via Benzinga
Here's How Much $100 Invested In AbbVie 10 Years Ago Would Be Worth Today
Via Benzinga
AbbVie Dividend Increase
Via Talk Markets
Price Over Earnings Overview: AbbVie
Via Benzinga
Market Analysis: AbbVie And Competitors In Biotechnology Industry
Via Benzinga
Is Eli Lilly a Buy? Analyst Confidence Grows for 2025
Via MarketBeat
Merck vs. Bristol-Myers: Analyst Views Differ After Q3 Earnings
Via MarketBeat
Topics Intellectual Property
Exposures Intellectual Property
High-Yield AbbVie Gains Momentum: A 20% Upside Is in Sight
Via MarketBeat
Topics Intellectual Property
Exposures Intellectual Property
Bristol Myers Squibb Stock Gets Relative Strength Rating Upgrade
Via Investor's Business Daily
AbbVie's Options Frenzy: What You Need to Know
Via Benzinga
Stock Market Retreats Before Election Day; Microsoft, Apple, Amazon, Google, Meta In Focus: Weekly Review
Via Investor's Business Daily
5 Dividend Stocks to Double Up on Right Now -- Plus Some Dividend ETFs
Via The Motley Fool
AbbVie’s Dividend Isn’t As Scary As It Looks
Via Talk Markets
Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights
Via Benzinga
Wall Street Mixed, Semiconductors Tumble As AMD Disappoints, Alphabet Rallies, SMCI Plummets: What's Driving Markets Wednesday?
Via Benzinga
AbbVie (ABBV) Q3 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
AbbVie Tops Q3 Expectations As Skyrizi, Rinvoq Drive Growth
Via Benzinga
AbbVie Has A New Cash Cow As Humira Bows To Skyrizi In Third-Quarter Beat
Via Investor's Business Daily
3 Dividend Growth Stocks to Buy and Never Sell
Via The Motley Fool
Biotech Momentum Trades For The Q4 Rally
Via Talk Markets
AbbVie Chart Reflects Bearish Signals Ahead Of Q3 Earnings
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.